A Single Center,Randomized Controlled Trial on the Efficacy of Topical Application of ReGenerating Tissue Agents (RGTA) Technology in Diabetic Foot Ulcers

Abstract

Diabetic foot ulcers (DFUs) are a serious complication of diabetes mellitus. Clinical data from the use of ReGenerating Tissue Agents (RGTA) technology in patients with DFUs are scarce. The objective of this randomized controlled study was to evaluate the efficacy of RGTA technology in the management of DFUs. Patients with chronic, neuroischemic diabetic foot ulcers were randomized 1:1 to the control group, that received the standard of care, and to the intervention group, that additionally received RGTA twice per week. The duration of the intervention was 12 weeks. Skin biopsies for histological and immunohistochemical analyses from a sample of participants were also performed. About 31 patients completed the study. Five (31.2%) patients in the intervention group achieved complete healing at the end of the intervention period versus 0 patients in the control group (P = .043), [RR: 0.688 (95% CI: 0.494-0.957)]. The intervention group had more ulcers with at least 80% healing of their surface [10 (66.7%) versus 2 (13.3%), P = .008, RR: 0.385 (95% CI: 0.183-0.808)], higher absolute surface reduction [1.5 (0.7, 5.2) versus 0.6 (0.3, 1.0), P = .026] and higher percentages of surface reduction [94 (67, 100) versus 40 (26, 75), P = .001] at the end of the intervention period. More patients in the intervention group achieved at least 50% healing at the fourth week of the study [9 (64.3%) versus 2 (14.3%) P = .018, RR: 0.417 (95% CI: 0.200-0.869)]. Immunohistochemical analyses were performed in a sample of participants that revealed higher expression of CD163, COL3 and VEGFR in the intervention group. The adverse effects were similar between the 2 groups. The data from the present study suggest that the adjunction of RGTA technology in the management of diabetic foot ulcers is a safe practice that promotes wound healing.

Keywords

diabetic foot ulcers < Lower extremity wound advanced treatments RGTA technology wound healing

Get full access to this article

View all access options for this article.

References

McDermott

Fang

Boulton

AJM

Selvin

Hicks

. Etiology, epidemiology, and disparities in the burden of diabetic foot ulcers. Diabetes Care. 2023;46(1):209-221. DOI: https://doi.org/10.2337/dci22-0043.

Eleftheriadou

Samakidou

Tentolouris

Papanas

Tentolouris

. Nonpharmacological management of diabetic foot ulcers: an update. Int J Low Extrem Wounds. 2021;20(3):188-197. DOI: https://doi.org/10.1177/1534734620963561.

International Diabetes Federation. The Diabetic Foot. 2020 6/1/2023. https://idf.org/our-activities/care-prevention/diabetic-foot.html.

Jeffcoate

Vileikyte

Boyko

Armstrong

Boulton

AJM

. Current challenges and opportunities in the prevention and management of diabetic foot ulcers. Diabetes Care. 2018;41(4):645-652. DOI: https://doi.org/10.2337/dc17-1836.

Baltzis

Eleftheriadou

Veves

. Pathogenesis and treatment of impaired wound healing in diabetes mellitus: new insights. Adv Ther. 2014;31(8):817-836. DOI: https://doi.org/10.1007/s12325-014-0140-x.

Schaper

van Netten

Apelqvist

Bus

Hinchliffe

Lipsky

. Practical guidelines on the prevention and management of diabetic foot disease (IWGDF 2019 update). Diabetes Metab Res Rev. 2020;36(Suppl 1):e3266. DOI: https://doi.org/10.1002/dmrr.3266.

Barritault

. Overview of 10 years of practice with CACIPLIQ20® matrix therapy as a healing agent for hard to heal wounds: efficacy, cost-effectiveness and future perspectives. Wound Medicine. 2020;28:100180. DOI: https://doi.org/10.1016/j.wndm.2020.100180.

Tong

Tuk

Hekking

Vermeij

Barritault

van Neck

. Stimulated neovascularization, inflammation resolution and collagen maturation in healing rat cutaneous wounds by a heparan sulfate glycosaminoglycan mimetic, OTR4120. Wound Repair Regen. 2009;17(6):840-852. DOI: https://doi.org/10.1111/j.1524-475X.2009.00548.x.

Tong

Tuk

Shang

, et al. Diabetes-impaired wound healing is improved by matrix therapy with heparan sulfate glycosaminoglycan mimetic OTR4120 in rats. Diabetes. 2012;61(10):2633-2641. DOI: https://doi.org/10.2337/db11-1329.

10.

Slim

Tajouri

Barritault

, et al. Matrix protection therapy in diabetic foot ulcers: pilot study of CACIPLIC20. J Int Wound Techno. 2012;17:14-20.

11.

Papanas

Demetzos

Pippa

Maltezos

Tentolouris

. Efficacy of a new heparan sulfate mimetic dressing in the healing of foot and lower extremity ulcerations in type 2 diabetes: a case series. Int J Low Extrem Wounds. 2016;15(1):63-67. DOI: https://doi.org/10.1177/1534734616629302.

12.

Schaper

. Diabetic foot ulcer classification system for research purposes: a progress report on criteria for including patients in research studies. Diabetes Metab Res Rev. 2004;20(Suppl 1):S90-S95. DOI: https://doi.org/10.1002/dmrr.464.

13.

Williams

Harding

Price

. An evaluation of the efficacy of methods used in screening for lower-limb arterial disease in diabetes. Diabetes Care. 2005;28(9):2206-2210. DOI: https://doi.org/10.2337/diacare.28.9.2206.

14.

Bus

Armstrong

Gooday

, et al. Guidelines on offloading foot ulcers in persons with diabetes (IWGDF 2019 update). Diabetes Metab Res Rev. 2020;36(Suppl 1):e3274. DOI: https://doi.org/10.1002/dmrr.3274.

15.

Jeffcoate

Bus

Game

Hinchliffe

Price

Schaper

. Reporting standards of studies and papers on the prevention and management of foot ulcers in diabetes: required details and markers of good quality. Lancet Diabetes Endocrinol. 2016;4(9):781-788. DOI: https://doi.org/10.1016/s2213-8587(16)30012-2.

16.

Sheehan

Jones

Caselli

Giurini

Veves

. Percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete healing in a 12-week prospective trial. Diabetes Care. 2003;26(6):1879-1882. DOI: https://doi.org/10.2337/diacare.26.6.1879.

17.

Coerper

Beckert

Küper

Jekov

Königsrainer

. Fifty percent area reduction after 4 weeks of treatment is a reliable indicator for healing–analysis of a single-center cohort of 704 diabetic patients. J Diabetes Complications. 2009;23(1):49-53. DOI: https://doi.org/10.1016/j.jdiacomp.2008.02.001.

18.

Rastogi

Kulkarni

Agarwal

, et al. Topical esmolol hydrochloride as a novel treatment modality for diabetic foot ulcers: a phase 3 randomized clinical trial. JAMA Network Open. 2023;6(5):e2311509-e2311509. DOI: https://doi.org/10.1001/jamanetworkopen.2023.11509.

19.

Game

Jeffcoate

Tarnow

, et al. Leucopatch system for the management of hard-to-heal diabetic foot ulcers in the UK, Denmark, and Sweden: an observer-masked, randomised controlled trial. Lancet Diabetes Endocrinol. 2018;6(11):870-878. DOI: https://doi.org/10.1016/s2213-8587(18)30240-7.

20.

Edmonds

Lázaro-Martínez

Alfayate-García

, et al. Sucrose octasulfate dressing versus control dressing in patients with neuroischaemic diabetic foot ulcers (explorer): an international, multicentre, double-blind, randomised, controlled trial. Lancet Diabetes Endocrinol. 2018;6(3):186–196. DOI: https://doi.org/10.1016/s2213-8587(17)30438-2.

21.

Barritault

Gilbert-Sirieix

Rice

, et al. RGTA(®) or ReGeneraTing agents mimic heparan sulfate in regenerative medicine: from concept to curing patients. Glycoconj J. 2017;34(3):325-338. DOI: https://doi.org/10.1007/s10719-016-9744-5.

22.

Dinh

Tecilazich

Kafanas

, et al. Mechanisms involved in the development and healing of diabetic foot ulceration. Diabetes. 2012;61(11):2937-2947. DOI: https://doi.org/10.2337/db12-0227.

23.

Barbier-Chassefière

Garcia-Filipe

Yue

, et al. Matrix therapy in regenerative medicine, a new approach to chronic wound healing. J Biomed Mater Res A. 2009;90(3):641-647. DOI: https://doi.org/10.1002/jbm.a.32124.

24.

Garcia-Filipe

Barbier-Chassefiere

Alexakis

, et al. RGTA OTR4120, a heparan sulfate mimetic, is a possible long-term active agent to heal burned skin. J Biomed Mater Res A. 2007;80(1):75-84. DOI: https://doi.org/10.1002/jbm.a.30874.

25.

Singh

Rai

Agrawal

. Regulation of collagen I and collagen III in tissue injury and regeneration. Cardiol Cardiovasc Med. 2023;7(1):5-16. DOI: https://doi.org/10.26502/fccm.92920302.

26.

Wang

Bove

Simone

. Molecular bases of VEGFR-2-mediated physiological function and pathological role. Front Cell Dev Biol. 2020;8:599281. DOI: https://doi.org/10.3389/fcell.2020.599281.

27.

Cheng

Shen

Mohanasundaram

, et al. Vimentin coordinates fibroblast proliferation and keratinocyte differentiation in wound healing via TGF-β-slug signaling. Proc Natl Acad Sci U S A. 2016;113(30):E4320-7. DOI: https://doi.org/10.1073/pnas.1519197113.

28.

Armstrong

Cohen

Courric

Bharara

Marston

. Diabetic foot ulcers and vascular insufficiency: our population has changed, but our methods have not. J Diabetes Sci Technol. 2011;5(6):1591-1595. DOI: https://doi.org/10.1177/193229681100500636.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.01 MB